Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT

Eur J Haematol. 2004 Dec;73(6):450-1. doi: 10.1111/j.1600-0609.2004.00321.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Disease
  • Adolescent
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / immunology
  • Antigens, Differentiation, Myelomonocytic / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm
  • Gemtuzumab
  • Humans
  • Immunization, Passive*
  • Immunoconjugates / therapeutic use
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / therapy*
  • Male
  • Remission Induction
  • Salvage Therapy*
  • Sialic Acid Binding Ig-like Lectin 3
  • Transplantation, Homologous

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Immunoconjugates
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab